Investment
Features
FeesSafety
Academy
More
Pluang+

Pfizer advances pneumococcal vaccine with strong Phase 2 results, starts Phase 3 in infants.

Company Fundamentals
20 May 2026
Vandana Singh
View Source
Bullish
pluang ai news

Pfizer reported positive Phase 2 results for its 25-valent pneumococcal conjugate vaccine, showing much stronger immune responses against serotype 3 compared to PREVNAR 20. The vaccine could cover up to 90% of disease-causing serotypes in children under five. Following these results, Pfizer launched a Phase 3 pediatric trial with up to 2,400 infants and plans to develop a 35-valent adult vaccine candidate by the end of 2026. This progress highlights Pfizer's commitment to expanding protection against pneumococcal disease in both children and adults.

More News (PFE)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App